Kevin Slawin In Portfolio, Rapha Capital Management NuMat Technologies Closes $12.4M Funding Round to Accelerate Commercialization of Molecularly Engineered Products Numat Technologies NuMat Technologies Closes $12.4M Funding Round to Accelerate Commercialization of Molecularly Engineered Products April 26, 2018 Read More
Kevin Slawin In Portfolio, Rapha Capital Management Poseida raises $30.5 million for cancer cell therapy Poseida Therapeutics Poseida raises $30.5 million for cancer cell therapy April 4, 2018 Read More